Paper Details

  1. Home
  2. Paper Details

Therapeutic Interferon Interchange in Relapsing Multiple Sclerosis Lowers Health Care and Pharmacy Expenditures with Comparable Safety.

Author: DelateThomas, HahnNicole, KlockeShilpa, PalmerKelsey E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Interferon (IFN) beta-1b subcutaneous is a medication used for treating relapsing multiple sclerosis (MS). This study aims to assess the effects of switching patients from IFN beta-1a to IFN beta-1b in a less-active form of MS.
Paper Details　
Original Abstract of the Article :
For patients with a less-active (fewer relapses or complete recovery from relapses, less radiologic burden of disease, or no or limited disease-related disability) relapsing form of multiple sclerosis (MS), interferon (IFN) beta-1b subcutaneous is similar in efficacy to IFN beta-1a intramuscular and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131095/

データ提供：米国国立医学図書館（NLM）

Therapeutic Interferon Interchange in Relapsing Multiple Sclerosis: Cost-Effectiveness and Safety

Interferon beta-1b is a commonly used medication for treating relapsing multiple sclerosis (MS). This study investigates the impact of switching patients from interferon beta-1a to interferon beta-1b, exploring the potential for cost savings and comparable safety. The researchers aimed to evaluate the effectiveness and cost-effectiveness of this therapeutic interchange in patients with relapsing MS.

Cost-Effectiveness and Safety of Interferon Beta-1b Interchange

The study found that switching patients from interferon beta-1a to interferon beta-1b resulted in lower healthcare and pharmacy expenditures without compromising safety. This suggests that interferon beta-1b can be a cost-effective alternative for treating relapsing MS, offering comparable efficacy and safety to interferon beta-1a.

Optimizing Treatment Strategies for Relapsing Multiple Sclerosis

This research provides valuable insights into the cost-effectiveness and safety of therapeutic interferon interchange in relapsing MS. The study suggests that interferon beta-1b can be a viable option for patients, offering comparable efficacy and cost savings. Further research is needed to explore the long-term outcomes of this therapeutic approach.

Dr.Camel's Conclusion

This research is like a camel caravan navigating the challenging terrain of multiple sclerosis treatment, seeking the most cost-effective and safe options for patients. The study explores the potential of switching from interferon beta-1a to interferon beta-1b, a strategy that may improve patient access to care and reduce healthcare costs. It’s like finding a hidden oasis in the desert – a reminder that innovation and cost-effectiveness can make a difference in managing this complex condition.

Date :
  1. Date Completed 2019-01-16
  2. Date Revised 2019-02-28
Further Info :

Pubmed ID

30201091

DOI: Digital Object Identifier

PMC6131095

Related Literature

Article Analysis
・Effects of interferon beta-1b injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.